Sequential CT Findings in Patients With Non–small-cell Lung Cancer Receiving Nivolumab
Abstract
Nivolumab is a novel immunotherapy that was recently approved for treatment of advanced non-small-cell lung cancer (NSCLC). Patients treated with checkpoint inhibitors may show variable computed tomography (CT) features on follow-up imaging, and it is unclear how reliable conventional response criteria are to determine patient management and outcomes. We report the spectrum of sequential CT findings in patients with advanced stage lung cancer...
Paper Details
Title
Sequential CT Findings in Patients With Non–small-cell Lung Cancer Receiving Nivolumab
Published Date
Mar 1, 2018
Journal
Volume
19
Issue
2
Pages
175 - 180
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History